Welcome to Stiefel India
This site is intented for India residents only.
Change location

  • Find us on:

Know More About Stiefel’s History

1980’s – 1990’s: International Growth

Stiefel Laboratories began the 1980s with six subsidiaries in major markets and many distributors. During the decade, 17 new subsidiaries were opened. Stiefel Laboratories’ first R&D facility outside of the U.S. was established in 1985 in Slough, a city near the company’s United Kingdom headquarters. (It was later moved to Maidenhead.) Another R&D facility was established in Brazil. At the close of the 1980s international sales had grown to nearly $50 million. The company’s operations continued to expand and by the 1990s Stiefel Laboratories boasted subsidiaries in more than 30 countries and relationships with distributors in 70 others. By the end of the decade, factories were operating in Ireland, Brazil, Singapore and Mexico, supplying markets around the world. Sales had reached $180 million.

1991: Glades Pharmaceuticals

Stiefel Laboratories founded Glades Pharmaceuticals to market generic dermatology products. Glades Pharmaceuticals later matured to market a full line of products including branded-generic and branded products. Brevoxyl®/Solugel® Creamy Wash is launched as the first benzoyl peroxide product containing dimethyl isosorbide to dissolve the benzoyl peroxide crystals and help reduce skin irritation.


Stiefel Laboratories introduced Isotrex® Gel as the world's first topical isotretinoin product.


Stiefel Laboratories introduced the Physiogel® -- a brand of skin care products that was the first family of "skin repair" products based on natural lipid, emulsifier-free repair technology.


Stiefel Laboratories was the first to market a combination of benzoyl peroxide and clindamycin for acne treatment. Stiefel Laboratories also established the brand of Versafoam®.


Stiefel Laboratories made its first major corporate acquisition when it acquired California-based Connetics Corporation, a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market.


Stiefel Laboratories introduced REVALÉSKIN®, the first and only professional
line of anti-aging skin care products exclusively formulated with the powerful
natural antioxidant ingredient, CoffeeBerry® Extract.


Stiefel Laboratories announced the promotion of William D. (Bill) Humphries to president of the privately-held dermatology company. Stiefel Laboratories completed the acquisition of Barrier Therapeutics, Inc. (“Barrier Therapeutics”) on August 6, 2008.


Stiefel Laboratories launched Impruv® Dry Skin Product for its consumer product portfolio.


GlaxoSmithKline completed the acquisition of Stiefel Laboratories, Inc., and announced that the new dermatology unit within GSK will operate under the name Stiefel, a GSK company.


Stiefel, a GSK company, launched The MaxClarity™ System, to bring acne innovation directly to consumers. The MaxClarity™ System uses VersaFoam® technology, which allows benzoyl peroxide and salicylic acid to penetrate the skin quickly and fight acne at the source before it become a pimple.


Stiefel, a GSK company, received FDA approval for two prescription products in the United States – VELTIN Gel, a topical acne treatment, and SORILUX™ Foam, a topical treatment for plaque psoriasis.


Stiefel, a GSK company, launched PanOxyl®, an over-the-counter formulation of the most-perscribed benzoyl perioxide acne wash.